Infusing factor Vlla (FVlla) has been reported to control bleeding in hemophilic patients with factor Vlll (FVIII) inhibitors. This is difficult to attribute to an enhanced FVlla/tissue factor (TF) activation of factor X. since in vitro studies suggest that infusion of FVlla should neither increase substantially the rate of formation of FVlla/TF complexes during hemostasis (Proc Natl Acad Sci USA 856687,1988) nor bypass the dampening of TF-dependent coagulation by the extrinsic pathway inhibitor (EPI) (Blood 73:359.1989). Partial thromboplastin times have also been reported to shorten after infusion of FVlla. The experiments reported herein establish that shortening of partial thromboplastin times after adding FVlla to hemophilic plasma in vitro stems from an FVlla-catalyzed activation of factor X independent of possible trace contamination of reagents with TF. Experiments in purified systems confirmed that FVlla can slowly activate factor X in a reaction N 1974, Kurczynski and Pennerl confirmed the successful I use of activated prothrombin complex concentrate to control bleeding in patients with factor VI11 (FVIII) inhibitors. Five years later, Seligsohn et alz reported that factor VIIa (FVIIa) present in such concentrates circulates with an intravascular half-time of over 2 hours, and suggested that circulating FVIIa might have a hemostatic effect in a hemophilic patient with an inhibitor. In 1983, Hedner and Kisie13 provided direct evidence for this; they used repeated infusions of microgram quantities of FVIJa purified from human plasma to control bleeding in two hemophilia A patients with inhibitors.
Recombinant FVIIa (rFVIIa) has now been isolated from a mammalian expression system: and Hedner et al' recently reported that repeated large doses (54 pg/kg) of this rFVIIa preparation prevented excessive bleeding during a synovectomy in a patient with hemophilia A and an inhibitor. Macik et a16 confirmed the clinical effectiveness of this preparation in a second patient with hemophilia A and an inhibitor. Moreover, Brinkhous et ai7 found that infusing a high concentration of the rFVIIa shortened the prolonged toenail bleeding time of dogs with hemophilia A or hemophilia B.
Thus, evidence grows that infusing FVIIa can control the bleeding resulting from impaired generation of the intrinsic activator of factor X (Factor IXa/VIIIa/phospholipid or membrane equivalent). But why infused FVIIa should be effective is unexplained. As suggested by the negative bleeding histories of persons with hereditary factor VI1 (FVII) deficiency who have levels of FVII activity above 10% when measured with human tissue factor (TF),' human plasma may well contain more than enough FVII to saturate T F sites exposed after vessel wall injury. Once bound to TF, FVII has been shown, in in vitro experiments, to be preferentially and very rapidly activated to FVIIa?." Moreover, an inhibitor, referred to as either extrinsic pathway inhibitor (EPI)" or lipoprotein-associated coagulation inhibitor,'* should form a complex with factor Xa as increasing amounts of factor Xa are generated at a wound site. The resultant EPI/factor Xa complex should then bind to FVIIa/TF and so inhibit further mixture containing Ca2+ and phospholipid but no source of TF. The rate of activation was sufficient to account for the shortening of partial thromboplastin times observed. EPI, which turned off continuing FVlla/TF activation of factor X, was unable to prevent continuing FVlla/phospholipid activation of factor X. Because circulating plasma contains only a trace, if any, free FVlla, such a reaction could never occur physiologically. However, infusing FVlla creates a nonphysiologic circumstance in which a continuing slow FVlla/ phospholipid catalyzed activation of factor X could conceivably proceed in vivo unimpeded by EPI. Such a mechanism of factor X activation might compensate for an impaired factor IXa/FVllla/phospholipid activation of factor X during hemostatis, and therefore control bleeding in a hemophilic patient. 0 1990 by The American Society of Hematology.
FVIIa/TF activation of factor X.I3 Consequently, it is difficult to believe that infusing FVIIa would enhance a direct FVIIa/TF activation of factor X sufficiently to bypass an impaired generation of factor X by its intrinsic activator.
The question then arises: could infused FVIIa activate factor X by a nonphysiologic mechanism independent of TF? @sterud14 demonstrated activation of factor X in a purified system containing factor X, FVIIa, phospholipid, and calcium. Such a reaction requiring only phospholipid as a cofactor could account for the shortening of partial thromboplastin times reported after infusing rFVIIa into patients and dogs with hem~philia~.~ or adding FVIIa to plasma in A TF-independent reaction should also bypass inhibition induced by an EPI/factor Xa complex. Therefore, we performed the experiments reported herein, which provide in vitro data supporting a hypothesis that the hemostatic effectiveness of infusions of FVIIa in patients with hemophilia stems from a FVIIa-catalyzed activation of factor X requiring phospholipid but independent of tissue factor. FVIII(a) . Because the FVIIa preparation contained factor Xa, a preparation was also made that contained factor Xa, cephalin, and calcium chloride, with buffer in place of FVII (sham preparation) for use as a control.
MATERIALS AND METHODS

Plasmas
Factor X and factor Xu. Purified human factor X, specific activity 105 U/mg, was prepared, activated to factor Xa with insolubilized Russell's viper venom, and stored as described earlier.'* Factor Xa specific activity was 1,207 U/mg. Human brain TF apoprotein was purified to homogeneity'' and incorporated into phospholipid vesicles containing 40% phosphatidylserine and 60% phosphatidylcholine as described previously."
TF antibodies. Specific polyclonal anti-rabbit TF immunoglobulin G (IgG)20 and specific polyclonal anti-human TF IgG" were prepared as described earlier. The purified IgG fractions were devoid of measurable contamination of factors IX and VI11 activities. A 10 pg/mL concentration of the anti-rabbit TF IgG neutralized about 90% of the coagulant activity of a 0.05 pg/mL preparation of reconstituted purified rabbit TF. A 4 pg/mL concentration of the anti-human TF IgG neutralized more than 95% of the coagulant activity of a 0.05 pg/mL preparation of reconstituted human TF.
The EPI preparation used in this study was partially purified from plasma by chromatography on Mono Q Sepharose (Pharmacia, Piscataway, NJ) as described earlier?'
A commercial activated partial thromobplastin time (APTT) reagent (Automated APTT, General Diagnostics, Raritan, NJ) was used for the APTT test, and rabbit brain cephalin (Sigma) was used for the partial thromboplastin time (PTT) test. One hundred microliters of citrated plasma containing different added test materials was incubated in a plastic tube with either 100 pL of APTT reagent or cephalin for 3 minutes at 37OC and then clotted by the addition of 100 pL of 35 mmol/L calcium chloride.
Factor Xa generated in purified reaction mixtures containing factor X; FVIIa; cephalin or TF, or buffer; and Caz+ was measured by its amidolytic activity against a chromogenic substrate (see the legends for Figs 2 and 3 for details).
Tissue factor (TFJ.
EPI.
Clotting assays.
Activation of factor X in apurifed system. As a positive control for the above experiment, the ability of anti-tissue factor IgG to abolish TF-induced shortening of the APTT of hemophilic plasmas was also tested. As apparent from the clotting times shown in Figs 1B and lC, adding 0.5 ng/mL of TF to hemophilia B plasma shortened the APTT as much as adding a 10,000-fold higher concentration of FVIIa (5 pg/mL). In contrast to its inability to prevent FVIIa-induced shortening, anti-tissue factor IgG abolished TF-induced shortening of the APTT.
RESULTS
Eflect of
The PTT differs from the APTT in that the contact FACTOR VHA-CATALYZED ACTIVATION OF FACTOR X 1071 activation reactions are only minimally activated. The PTT of hemophilia A and B plasmas consistently exceeded 10 minutes. Adding FVIIa in a final concentration of 5 pg/mL to these plasmas shortened the PTT to the 95 to 110 second range. As with the APTT, anti-tissue factor IgG had no significant effect on the shortening (Table 1) .
Since factor Xa was used to activate the FVII, it was necessary to establish that this factor Xa did not contribute significantly to the shortening induced by the FVIIa preparation. This was done in three ways. First, the FVIIa preparation was shown to shorten neither the PTT (Table 1) or the APTT of factor X-deficient plasma (about 85 seconds on adding to the factor X-deficient plasma, either buffer or an FVIIa preparation, 5 pg/mL). Second, adding the control sham FVIIa preparation (which contained factor Xa but no FVII) to hemophilic plasmas did not shorten the PTT (greater than 600 seconds), and shortened only minimally the APTT (Fig 1A) . Third, an FVIIa preparation made with factor Xa insolubilized on Affi-Gel 15 beads (Bio-Rad, Richmond, CA) and removed after incubation by filtration through a 0.2 pm nylon membrane (West Coast Scientific, Inc, Hayward, CA) also shortened the APTT of hemophilic plasma (data not shown).
However, one should note (see legends of Fig 1 and Table  1 ) that the hemophilic plasmas were allowed to stand for 20 minutes after adding the FVIIa preparation to allow time for neutralization of added factor Xa before the APTT and PTT were performed. Indeed, when factor Xa was added in increasing concentrations to the APTT reagent and this reagent was added just before the calcium to hemophilic plasma, a final concentration of only 5 ng/mL of factor Xa in the APTT reagent shortened the APTT to 45 seconds ( Fig  1D) . 
Activation of factor X by FVIIa in purified systems.
Because the above APTT and PTT data were interpreted to mean that FVIIa could activate factor X in hemophilic plasma in the absence of TF, further experiments were performed in purified systems to confirm this. Purified factor X was incubated in microtiter wells with varying concentrations of FVIIa and Ca2+ in the presence or absence of phospholipid. In the presence of phospholipid, increasing concentrations of FVIIa yielded increasing rates of factor X activation (Fig 2) . A 5 pg/mL concentration of FVIIa yielded a factor X activation rate of 27 ng/mL/min. In the absence of phospholipid, this concentration of FVIIa failed to activate measurable amounts of factor X.
When reaction mixtures were made with increasing concentrations of FVIIa and 2 ng/mL of purified, reconstituted TF, only 200 pg/mL of FVIIa was required to activate factor X at a rate comparable with that obtained with 5 pg/mL of FVIIa and phospholipid. When increasing concentrations of T F were added to reaction mixtures made with a 5 pg/mL concentration of FVIIa, 0.5 ng/mL of tissue factor yielded a factor X activation rate comparable with that observed with 5 pg/mL of FVIIa and phospholipid.
When FVIIa/TF catalyzes activation of factor X in reaction mixtures containing EPI, factor Xa can form an EPI/factor Xa complex that then shuts down further FVIIa/TF catalytic Experiments were performed to test whether EPI could similarly shut down FVIIa/phospholipid catalyzed activaEffect of EPI on factor X activation. tion of factor X. Reaction mixtures were made to contain constant concentrations of factor X, FVIIa, and calcium ions, increasing concentrations of EPI, and either TF or phospholipid. Concentrations of tissue factor and phospholipid were used that yielded similar factor X activation in reaction mixtures containing buffer instead of EPI. Factor Xa activity was measured after 30 minutes of incubation. Data from 1 of 3 experiments giving similar results are summarized in Fig 3. As expected, EPI suppressed FVIIa/ TF activation of factor X. In contrast, EPI failed to suppress FVIIa/phospholipid activation of factor X. (The minor reduction in factor Xa activity of reaction mixtures containing phospholipid is thought to reflect the known ability of EPI to neutralize factor Xa amidolytic activity.)'z22
DISCUSSION
It is generally accepted that FVII must form a complex with TF to function in normal hemosta~is.2~ Nevertheless, the data reported herein support a hypothesis that a minimal but continuing FVIIa-catalyzed activation of factor X, requiring phospholipid but independent of TF, could be a mechanism whereby infusions of FVIIa control bleeding in patients and experimental animals with impaired factor IXa/FVIIIa/ phospholipid catalyzed activation of factor X. Three types of indirect supporting evidence for this hypothesis were obtained. First, it was shown that a TF-independent, FVIIacatalyzed activation of factor X can account for the previously unexplained shortening of PTTs reported after infusion of rFVIIa6*' or adding FVIIa to hemophilic plasma in vitro.'.'' Second, it was confirmed in a purified system that FVIIa can activate factor X in the presence of Ca2+ and phospholipid. Third, it was shown that EPI, in contrast to its effectiveness in dampening FVIIa/TF activation of factor X, cannot inhibit FVIIa/phosphilipid activation of factor X. Shortening of APTT and PTT test results by FVIIa could have had two possible explanations: contamination of test reagents with traces of TF or FVIIa catalyzed activation of factor X independent of TF. The second explanation was proven correct. Adding anti-tissue factor IgG abolished shortening of the APTT induced by adding TF to hemophilic plasma mixtures (Fig lC) , whereas adding anti-tissue factor IgG had no effect on the shortening of the APTT and PTT induced by adding FVIIa to hemophilic plasma (Fig 1B and Table I ). The low concentration of factor Xa in the FVIIa preparation had no appreciable effect on the APTT (Fig 1A) or PTT, undoubtedly because the plasma was allowed to stand for 20 minutes to neutralize the factor Xa before the tests were performed. Therefore, the shortening of the APTT and PTT observed after adding the FVIIa preparation to hemophilic plasmas (Fig 1, A and B , and Table 1 ) had to stem from a TF-independent, FVIIa-catalyzed activation of factor X during the tests.
In additional experiments, low concentrations of factor Xa were added to the APTT reagent and the resultant mixture added to warmed hemophilia B plasma just before the calcium. Under these conditions, which minimized neutralization of factor Xa before the test, only 5 ng/mL of factor Xa in the APTT reagent shortened clotting times to those obtained in the standard APTT test after adding 5 pg/mL FVIIa to hemophilic plasma (compare clotting times of Figs lA, B, and D). One should note that an FVIIa-catalyzed generation of 5 ng/mL of factor Xa in the standard APTT test would require activation of less than 0.1% of factor X in the test mixture (assuming a factor X concentration in the hemophilic plasma of 8 pg/mL).
The experiments in purified systems (Fig 2) confirm and extend hterud's earlier ob~ervation'~ that factor X can be activated with FVIIa, Ca", and phospholipid. The rates of generation of factor Xa measured were sufficient to account for the shortening of the APTT induced by adding FVIIa to hemophilic plasmas (see Figs 1D and 2) . Nevertheless, the enzymatic efficiency of FVIIa/phospholipid was minimal compared with that of FVIIa/TF, eg, 5 pg/mL FVIIa with phospholipid yielded a rate of activation equivalent to that obtained with 0.2 ng/mL of FVIIa in the presence of TF.
Consequently, one might assume that a slow FVIIa/ phospholipid activation of factor X would be of no hemostatic significance. However, EPI could not inhibit generation of factor Xa in a reaction mixture made with factor X, FVIIa, and phospholipid, whereas EPI markedly diminished generation of factor Xa in a reaction mixture made with factor X, FVIIa, and a low concentration of tissue factor (Fig 3) . Thus, if a limited number of FVIIa/TF complexes are formed at a wound site and subsequently inhibited by EPI/factor Xa, then FVIIa/phospholipid complexes formed at the wound site might well provide a slow but hemostatically meaningful mechanism for continuing the activation of factor X.
When normal human plasma was clotted in vitro with diluted crude brain tissue factor, barely measurable amounts of free plasma FVIIa were generated.I7 Moreover, when rabbits were infused with a concentration of TF that caused mean fibrinogen levels to fall to about 10% of the level before infusion, no circulating FVIIa was demonstrable."*2s Thus, it is unlikely that plasma normally ever contains more than a trace of free FVIIa,26 so the free FVIIa needed for an FVIIa/phospholipid activation of factor X is not available. A factor IXa/FVIIIa/phospholipid (or membrane equivalent) activation of factor X is the mechanism whereby EPIdampened FVIIa/TF activation of factor X is supplemented in normal human hemo~tasis.'~ When this mechanism fails, as in hemophilic patients, serious bleeding results.
However, if one raises plasma FVIIa concentration by infusing FVIIa, then an FVIIa/phospholipid-catalyzed activation of factor X might be able to compensate for an impaired factor IXa/FVIIIa/phospholipid activation of factor X. The known intravascular half-time of FVIIa is about 2% hours' and the presumed presence of the required phospholipid cofactor on aggregated, activated platelets and tissue cells at a wound site makes this a feasible possibility. The hypothesis is attractive to us because it permits one to reconcile the evidence that infused FVIIa controls hemophilics' bleeding with present concepts of the initiation and regulation of the tissue factor pathway of coag~lation.'~ It could explain why infusing FVIIa would have a hemostatic effect, despite a plasma concentration of FVII sufficient to saturate T F at an injury site, and the preferential, rapid activation to FVIIa of FVII bound to TF.9710 Most importantly, one can then understand why infusing FVIIa would bypass regulation by EPI of FVIIa/TF catalytic activity. However, we must emphasize that our in vitro data cannot extrapolate with certainty to explain the mode of action of high concentration of infused FVIIa in vivo. Our next step is to test this hypothesis further with in vivo experiments to elucidate the mechanism whereby the infusion of rFVIIa controls bleeding in hemophilics.
